Search results for "OSTEONECROSIS OF THE JAW"

showing 10 items of 143 documents

Intravenous bisphosphonate-related osteonecrosis of the jaws: Influence of coadjuvant antineoplastic treatment and study of buccodental condition

2012

Objectives: To determine whether coadjuvant antineoplastic treatment can influence the number and size of bone exposures among patients with intravenous bisphosphonate-related osteonecrosis of the jaws (iBRONJ), and to analyze the buccodental condition of these patients. Material and methods: The study sample comprised 67 patients with iBRONJ, 53 patients without iBRONJ receiving treatment with intravenous bisphosphonates, and 36 healthy subjects. In all three groups, measurements were made of the CAO index and of resting whole saliva and stimulated whole saliva. In the patients with iBRONJ, the size (cm) and number of bone exposures were recorded. The data obtained were subjected to analys…

MaleMultivariate statisticsmedicine.medical_treatmentDentistryOdontologíaAntineoplastic AgentsLogistic regressionIntravenous bisphosphonatesmedicineHumansWhole salivaGeneral DentistryBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologyDiphosphonatesbusiness.industryHealthy subjectsBisphosphonateMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludOtorhinolaryngologyChemotherapy AdjuvantUNESCO::CIENCIAS MÉDICASInjections IntravenousSurgeryResearch-ArticleBisphosphonate-Associated Osteonecrosis of the JawFemaleAnalysis of variancebusinessMouth DiseasesMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multic…

2015

Osteonecrosis of the jaw (ONJ) associated with the use of bisphosphonates has been rarely reported in metastatic renal cell cancer (RCC) patients. Since the introduction of combined therapies consisting of nitrogen-containing bisphosphonates (NBPs) and targeted agents, an increasing number of RCC patients were reported to develop ONJ, suggesting that therapeutic angiogenesis suppression might increase the risk of ONJ in NBPs users. We performed a multicenter retrospective study and reviewed literature data to assess the occurrence and to investigate the nature of ONJ in RCC patients taking NBPs and targeted agents. Nine Italian Centers contributed to the data collection. Patients with expos…

MaleOncologyIndolesAngiogenesis InhibitorsPyrroleBevacizumab; m-TOR inhibitor; Sorafenib; Sunitinib; Zoledronic acidRetrospective StudieAntineoplastic Combined Chemotherapy ProtocolsSunitinibAged 80 and overDiphosphonatesSunitinibImidazolesOsteonecrosisKidney NeoplasmMiddle AgedSorafenibKidney NeoplasmsBevacizumabDiphosphonateItalyOncologyOsteonecrosiFemaleAngiogenesis InhibitorHumanmedicine.drugSorafenibmedicine.medical_specialtyBevacizumab; m-TOR inhibitor; Sorafenib; Sunitinib; Zoledronic acid; Aged; Aged 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Indoles; Italy; Jaw; Kidney Neoplasms; Male; Middle Aged; Osteonecrosis; Pyrroles; Retrospective Studies; Oncology; UrologyBevacizumabUrologyInternal medicinemedicineHumansPyrrolesIn patientMetastatic renal cell cancerImidazoleCarcinoma Renal CellZoledronic acidAgedRetrospective StudiesAntineoplastic Combined Chemotherapy Protocolbusiness.industryRetrospective cohort studymedicine.diseasem-TOR inhibitorSurgeryZoledronic acidJawIndolebusinessOsteonecrosis of the jaw
researchProduct

Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab.

2014

Dear Editor, The paper by Henry et al. published by Supportive Care in Cancer comparing efficacy of denosumab versus zoledronic acid in patients with bone metastases of advanced solid tumours [1] comes to integrate the original reports of three pivotal large randomized phase 3 trials [2–4], the publication by Saad et al. about osteonecrosis of the jaw (ONJ) in those three trials [5], and the combined outcome analysis by Lipton et al. [6]. Henry et al. [1] reported outcomes of the single trial conducted on patients with solid tumours (except breast or prostate cancers, object of other two trials) [2, 3], excluding patients with multiple myeloma: This ad hoc analysis confirmed the superiority…

MaleOncologymedicine.medical_specialtyBevacizumabONJ renal cell cancerBone NeoplasmsAntibodies Monoclonal HumanizedPazopanibSettore MED/28 - Malattie OdontostomatologicheNeoplasmsInternal medicinemedicineHumansBone ResorptionEverolimusBone Density Conservation AgentsDiphosphonatesSunitinibbusiness.industryImidazolesmedicine.diseaseTemsirolimusZoledronic acidDenosumabOncologyFemalebusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Dental extraction following zoledronate, induces osteonecrosis in rat´s jaw

2017

Background Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) is clinically characterized by the presence of exposed bone in the oral cavity that persists for more than eight weeks. Previous attempts to establish an animal model have not sufficiently considered disease features. Our aim was to establish an inexpensive and replicable animal model that develops BRONJ in a short time. Material and Methods Thirty-two male Wistar rats were randomly divided into two groups: control and experimental. In the experimental group, we administered 0.06mg/kg intraperitoneal dose of zoledronic acid (ZA) 7 and 14 days prior to maxillary second molar extraction. At two, four and six weeks after tooth …

MalePathologymedicine.medical_specialtymedicine.medical_treatmentMaxillary second molarH&E stainZoledronic AcidSequestrumRandom Allocation03 medical and health sciencesPostoperative Complications0302 clinical medicineTrichromemedicineAnimalsRats WistarGeneral DentistryOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchImidazoles030206 dentistry030224 pathologymedicine.disease:CIENCIAS MÉDICAS [UNESCO]RatsDisease Models AnimalZoledronic acidOtorhinolaryngologyDental extractionMaxillaTooth ExtractionUNESCO::CIENCIAS MÉDICASBisphosphonate-Associated Osteonecrosis of the JawSurgeryOsteonecrosis of the jawbusinessmedicine.drug
researchProduct

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

2017

Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…

MalebisphosphonateTime Factorsmedicine.medical_treatmentOsteoporosis0302 clinical medicineRisk Factors80 and overosteoporosijaw osteonecrosiAged 80 and overBone Density Conservation AgentsDiphosphonatesjaw osteonecrosisjaw osteonecrosis bisphosphonates breast cancer multiple myeloma prostate cance osteoporosisIncidenceIncidence (epidemiology)Otorhinolaryngology2734 Pathology and Forensic MedicineMiddle Agedprostate cancermultiple myeloma030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleAdultmedicine.medical_specialty2734Drug Administration SchedulePathology and Forensic Medicine03 medical and health sciencesbreast cancerbisphosphonates; breast cancer; jaw osteonecrosis; multiple myeloma; osteoporosis; prostate cancer; Adult; Aged; Aged 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Otorhinolaryngology; 2734; Pathology and Forensic Medicine; Dentistry (all)Internal medicinemedicineHumansBisphosphonates; Breast cancer; Jaw osteonecrosis; Multiple myeloma; Osteoporosis; Prostate cancer; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)prostate canceAdverse effectGeneral DentistrybisphosphonatesAgedProportional Hazards ModelsRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseosteoporosisSurgeryCross-Sectional StudiesOtorhinolaryngologyMultivariate AnalysisDentistry (all)businessOsteonecrosis of the jaw
researchProduct

Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures

2012

There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized. INTRODUCTION: The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ. METHODS: An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case-control study within a cohort of individuals aged 55+ years old, who w…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismONJDentistryOsteoporosis; fractures; biphosphonatesAdministration OralBisphosphonates Nested case–control study Osteonecrosis of the jaw Osteoporotic fracturesOSTEPOROSISRisk AssessmentAssociationADMINSTRATIVE DATABASESnested case-control studySettore MED/28 - Malattie OdontostomatologicheClaims dataMedicineHumansnested case-control study; osteoporotic fractures; osteonecrosis of the jaw; bisphosphonatesWomenbisphosphonatesAgedSecondary preventionAged 80 and overOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryMiddle Agedmedicine.diseaseOral BisphosphonateNecrosiosteonecrosis of the jawItalyClaims DataCase-Control StudiesOrthopedic surgeryBisphosphonates; Osteonecrosis of the jaw; Osteoporotic fractures; Nested case-control studyBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgeryProfileBisphosphonate therapyMedical Record LinkagebusinessOsteonecrosis of the jawOsteoporotic Fractures
researchProduct

Bisphosphonate-related osteonecrosis of the jaws (Bronj).

2011

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is an extremely therapy resistant osteomyelitis-like disease exclusively involving the jaw bones of patients in treatment with bisphosphonates (BPs). Objectives: The aim of this study was to evaluate the radiological and clinical findings and management of 51 patients with BRONJ diagnosed from 2004 to 2009 in our Reference Center. Study Design: A prospective study was performed. The patients were examined every 2-6 months, depending on their clinical conditions. Outcome variables were the resolution of symptoms, persistence of bone exposure and / or fistula and the status of the lesional mucosa. Results: The higher prevalence of the d…

Malemedicine.medical_specialtyFistulamedicine.medical_treatmentOdontologíaOsteotomySequestrummedicineHumansProspective StudiesProspective cohort studyGeneral DentistryPathologicalAgedBisphosphonate-associated osteonecrosis of the jawOral Medicine and Pathologybusiness.industryBisphosphonatemedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludCurettageSurgeryOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleResearch-ArticlebusinessFollow-Up StudiesMedicina oral, patologia oral y cirugia bucal
researchProduct

A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid…

2017

Background The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. Material and Methods This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms. Results Of the 156 patients enrolled in the study, 17 developed ONJ (10.89%). At the multivariate analysis, severe periodontal disease (P=0.025), tooth extraction (P<0.0001) and starting the preventive dental program af…

Malemedicine.medical_specialtyLongitudinal studyTime FactorsBone NeoplasmsZoledronic Acid03 medical and health sciences0302 clinical medicinestomatognathic systemRisk FactorsmedicineHumansIn patientLongitudinal StudiesGeneral DentistryAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ResearchIncidenceImidazolesRetrospective cohort study030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseMedically compromised patients in DentistrySurgeryBone Density Conservation Agentsstomatognathic diseasesZoledronic acidOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Association between periodontal disease and prostate cancer: a systematic review and meta-analysis

2021

Background Periodontal disease is a chronic infectious disease caused by bacterial infection which may lead to various systematic diseases. Recently, increasing studies have explored the correlation of periodontal disease with the risk of prostate cancer. However, the findings were inconsistent. Hence, this study aims to investigate the association between periodontal disease and the risk of prostate cancer by a meta-analysis. Material and Methods PubMed, EMBASE, and Cochrane were searched for publications up to July 17, 2020. Cohort and case-control studies evaluating the risk of prostate cancer in patients with periodontal disease were included. A fixed or random-effect model was used to …

Malemedicine.medical_specialtyMEDLINEReviewCohort Studieszoledronic acid03 medical and health sciencesProstate cancer0302 clinical medicinePeriodontal diseaseRisk FactorsInternal medicineHumansMedicinePeriodontologyIn patientbisphosphonatesGeneral DentistryPeriodontal DiseasesUNESCO:CIENCIAS MÉDICASbusiness.industryProstatic Neoplasmsdenosumab030206 dentistrymedicine.diseaseConfidence intervalosteonecrosis of the jawOtorhinolaryngologyCase-Control StudiesMeta-analysisRelative riskCohortincidenceSurgerybusinessantiangiogenic drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain

2011

Objective: The objective of this study was to define the clinical characteristics of osteonecrosis of the jaws (ONJ) induced by oral bisphosphonates in a series of patients from a circumscribed area in northwest Spain. Study Design:A retrospective multicentre study was undertaken in 3 hospitals in an area with a radius less than 100 km in the Autonomous Community of Galicia (Spain). The medical records were reviewed and an oral examination was performed of patients diagnosed with oral bisphosphonate-related ONJ in the previous 3 years. Results: We detected 20 cases of ONJ (24 lesions) related to oral bisphosphonates (alendronate [16 patients] and ibandronate [4 patients]), which were mainly…

Malemedicine.medical_specialtyOsteoporosisCorticosteroid treatmentDiabetes mellitusmedicineHumansStage (cooking)Ibandronic AcidGeneral DentistryAgedRetrospective StudiesAged 80 and overSeries (stratigraphy)Oral Medicine and PathologyOral bisphosphonatesAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryMedical recordMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASOral examinationBisphosphonate-Associated Osteonecrosis of the JawFemaleResearch-ArticleSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct